CMPS.NASDAQCompass Pathways PLC

SCHEDULE: ATAI Life Sciences Trims COMPASS Pathways Stake

Sentiment:

Beneficial Ownership Update

📋All filings for Compass Pathways PLC
🔒Login to Follow

ATAI Life Sciences N.V. reported a reduction in its beneficial ownership of COMPASS Pathways plc to 6.0% following recent open market sales.

Worse than expectedATAI Life Sciences N.V. reduced its beneficial ownership in COMPASS Pathways plc by selling 220,000 ADSs, indicating a decrease in its investment in the company.

Summary

  • ATAI Life Sciences N.V. now beneficially owns 5,785,774 Ordinary Shares of COMPASS Pathways plc.
  • This represents approximately 6.0% of the 95,941,264 Ordinary Shares outstanding as of July 28, 2025.
  • ATAI N.V. conducted open market sales of 220,000 American Depositary Shares (ADSs) between October 22, 2025, and October 28, 2025, at prices ranging from $6.2949 to $6.5801 per share.
  • A corporate reorganization in April 2025 resulted in ATAI Life Sciences AG converting to a German GmbH and ceasing beneficial ownership, with shares now held directly by ATAI Life Sciences N.V.

Sentiment

Score: 4

Explanation: The reduction in a significant investor's stake, while not a complete divestment, generally signals a less positive outlook from that investor, potentially impacting market sentiment negatively for the issuer.

Negatives

  • ATAI Life Sciences N.V. reduced its stake in COMPASS Pathways plc by selling 220,000 ADSs in the open market.
  • The reduction in beneficial ownership from a significant holder like ATAI could be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance provided in this filing.

Industry Context

This filing reflects a change in a significant investor's position in a biotechnology company focused on mental health treatments, specifically psychedelics. Such changes can signal shifts in investor confidence or portfolio rebalancing within the sector.

Stakeholder Impact

  • Shareholders: Existing shareholders may view the reduction in ATAI's stake negatively, potentially leading to downward pressure on the share price.

Key Dates

DateDescription
May 24, 2021Original Schedule 13D filed with the SEC.
April 2025Corporate reorganization where ATAI Life Sciences AG converted into a German GmbH and ceased beneficial ownership.
July 28, 2025Date for which 95,941,264 Ordinary Shares outstanding were disclosed in the Issuer's Form 10-Q.
July 31, 2025Date Issuer's Quarterly Report on Form 10-Q was filed.
October 22, 2025ATAI N.V. sold 20,000 ADSs at $6.3194 per share.
October 23, 2025ATAI N.V. sold 20,000 ADSs at $6.2949 per share.
October 24, 2025ATAI N.V. sold 60,000 ADSs at $6.3714 per share.
October 27, 2025Date of event requiring filing of this statement; ATAI N.V. sold 60,000 ADSs at $6.5801 per share.
October 28, 2025ATAI N.V. sold 60,000 ADSs at $6.4946 per share.
October 29, 2025Date of signature for the Schedule 13D Amendment No. 5.

Recommendation

hold

While a significant investor has reduced its stake, the remaining 6.0% ownership by ATAI Life Sciences N.V. still represents a substantial position. The sales occurred over several days at varying prices, suggesting a managed reduction rather than an abrupt exit. Investors should monitor future filings and company performance, but a 'hold' recommendation is appropriate given the partial reduction and continued significant stake.

Keywords

COMPASS Pathways, CMPS, ATAI Life Sciences, Schedule 13D, Beneficial Ownership, Share Sales, SEC Filing, Biotechnology, Psychedelics, Investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.